Search company, investor...

Total Raised

$153.68M

Investors Count

18

Deal Terms

6

Funding, Valuation & Revenue

12 Fundings

Mitralign has raised $153.68M over 12 rounds.

Mitralign's latest funding round was a Series F for $9.77M on February 20, 2018.

Mitralign's valuation in October 2012 was $105.32M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/20/2018

Series F

$9.77M

Undisclosed Investors

$99M

0

FY undefined

2

5/17/2016

Series E

$39.8M

Undisclosed Investors

$99M

0

FY undefined

4

6/20/2014

Unattributed VC

$8.05M

$99M

0

FY undefined

1

10/29/2012

Series D - II

$99M

$105.32M

0

FY undefined

0

9/12/2012

Debt - II

$99M

$99M

0

FY undefined

10

Date

2/20/2018

5/17/2016

6/20/2014

10/29/2012

9/12/2012

Round

Series F

Series E

Unattributed VC

Series D - II

Debt - II

Amount

$9.77M

$39.8M

$8.05M

$99M

$99M

Investors

Undisclosed Investors

Undisclosed Investors

Valuation

$99M

$99M

$99M

$105.32M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

4

1

0

10

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Mitralign Deal Terms

6 Deal Terms

Mitralign's deal structure is available for 6 funding rounds, including their Unattributed VC from June 20, 2014.

Round

Unattributed VC

Series D - II

Series D

Series C

Series B

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

$99M

$99M

Dividend Rate

$99M

$99M

$99M

Liquidation Preferences

$99M

$99M

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Unattributed VC

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D - II

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Mitralign Investors

18 Investors

Mitralign has 18 investors. Oxford Bioscience Partners invested in Mitralign's Unattributed VC funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

6/1/2005

6/20/2014

7
Series A, Series A - II (2005), Series B (2006), Series C (2007), Series D (2012), Series D - II (2012), Unattributed VC (2014)

Venture Capital

Massachusetts

12/14/2007

6/20/2014

4
Series C, Series D (2012), Series D - II (2012), Unattributed VC (2014)

Venture Capital

Netherlands

4/6/2006

6/20/2014

4
Series B, Series C (2007), Series D (2012), Unattributed VC (2014)

Carolyn Bates

Venture Capital

Ohio

00/00/0000

00/00/0000

Accelerated Technologies Partners

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Horizon Technology Finance

Subscribe to see more

Debt & Specialty Finance

Connecticut

First funding

6/1/2005

12/14/2007

4/6/2006

00/00/0000

00/00/0000

Last Funding

6/20/2014

6/20/2014

6/20/2014

00/00/0000

00/00/0000

Investor

Accelerated Technologies Partners

Horizon Technology Finance

Rounds

7
Series A, Series A - II (2005), Series B (2006), Series C (2007), Series D (2012), Series D - II (2012), Unattributed VC (2014)
4
Series C, Series D (2012), Series D - II (2012), Unattributed VC (2014)
4
Series B, Series C (2007), Series D (2012), Unattributed VC (2014)

Subscribe to see more

Subscribe to see more

Board Seats

Carolyn Bates

Type

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Debt & Specialty Finance

Location

Massachusetts

Netherlands

Ohio

New York

Connecticut

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Mitralign to Competitors

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

Cardiac Dimensions Logo
Cardiac Dimensions

Cardiac Dimensions is a company focused on improving the treatment of heart failure in the healthcare sector. The company offers a non-surgical device, designed to treat patients with mitral valve insufficiency, which works with the natural structure and function of the heart to treat the condition and related symptoms. The company primarily sells to the healthcare industry. It was founded in 2000 and is based in Kirkland, Washington.

Avertix Logo
Avertix

Avertix develops an implantable cardiac monitoring and alerting system to warn cardiac patients of potentially life-threatening heart conditions. It offers heart monitors that track changes in the heart's electrical signal from a pacemaker lead. It identifies the symptoms of acute thrombotic occlusions by alerting the patient to seek medical attention. The firm was formerly known as Angel Medical Systems and changed its name to Avertix in April 2023. The company was founded in 2001 and is based in Eatontown, New Jersey.

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

B
Bio Control Medical

Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

C
CardioKinetix

CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.